Combining GLP-1, glucagon, and GIP receptor agonists improved NASH liver scores beyond what liraglutide alone achieved, even at comparable weight loss.
Weight-independent liver benefittriple incretin combination improved NASH beyond what weight loss alone would predict, suggesting direct liver protective mechanisms
What the researchers found
Mice were fed a high-fat, high-fructose, high-cholesterol diet for 36 weeks to develop NASH with fibrosis, then treated for 8 weeks. Low-dose glucagon or GIP alone did not affect body weight, liver fat, or liver damage scores. But when combined with GLP-1 receptor activation, both glucagon and GIP provided additional benefits.
The triple combination (GLP-1 + glucagon + GIP) and a dual GLP-1/glucagon peptide both significantly reduced the NAFLD activity score more than high-dose liraglutide. This happened at comparable levels of weight loss, meaning the extra liver improvement came from the hormones themselves, not just from losing weight.
This supports the idea that multi-receptor agonists targeting two or three gut hormone receptors could be more effective for NASH than GLP-1 drugs alone.
Why it matters
NASH is a leading cause of liver disease with limited treatment options. Current GLP-1 drugs help partly through weight loss, but this study shows that adding glucagon and GIP receptor activation provides liver benefits beyond what weight loss alone can explain.
This research supports the development of multi-agonist drugs like tirzepatide and experimental triple agonists for liver disease.
The numbers in context
36 weeks diet + 8 weeks treatment; triple combo and dual peptide beat liraglutide on NAFLD activity score at comparable weight loss
How the study worked
Mice were pre-fed a NASH-inducing diet for 36 weeks, then treated for 8 weeks with subcutaneous injections of individual receptor agonists (GLP-1, glucagon, GIP), dual or triple combinations, a dual GLP-1/glucagon peptide, or liraglutide. Researchers measured body weight, liver triglycerides, and histological disease scores.
Who was studied
C57BL/6J mice with diet-induced NASH and fibrosis
What this study cannot tell us
This was a mouse study using a diet-induced NASH model, which does not perfectly replicate human NASH. The 8-week treatment period may not capture longer-term effects or safety concerns.
The individual agonist doses were low, which may explain why they had no effect alone. Higher doses might have shown different results.
How to read the evidence
Moderate evidence from a well-designed mouse study. NASH models have limitations but the head-to-head comparisons are informative.
When this study was published
Published in 2020. Tirzepatide (dual GIP/GLP-1) has since been approved, and triple agonists are in clinical development.
The bigger picture
NASH is becoming the leading cause of liver transplants worldwide. Current GLP-1 drugs help partly through weight loss, but this study shows direct liver benefits from adding glucagon and GIP activation. This supports the multi-agonist approach exemplified by tirzepatide and future triple agonists.
Questions still open
- What are the direct liver mechanisms of glucagon and GIP receptor activation?
- Will human NASH patients show the same additive benefits?
- How does the triple combination compare to emerging NASH-specific drugs?
Common questions
What is NASH and why is it dangerous?
Why combine multiple hormone agonists for liver disease?
Read the original research
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.
Diabetes, obesity & metabolism, 22(8), 1328-1338
Citation
Kannt, Aimo; Madsen, Andreas Nygaard; Kammermeier, Claire; Elvert, Ralf; Klöckener, Tim; Bossart, Martin; Haack, Torsten; Evers, Andreas; Lorenz, Katrin; Hennerici, Wolfgang; Rocher, Corinne; Böcskei, Zsolt; Guillemot, Jean-Claude; Mikol, Vincent; Pattou, Francois; Staels, Bart; Wagner, Michael. (2020). Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.. Diabetes, obesity & metabolism, 22(8), 1328-1338. https://doi.org/10.1111/dom.14035